Bomedemstat

Ruxolitinib, approved in 2011 for myelofibrosis (MF), is key in treating MF and polycythemia vera (PV). Despite its benefits, some patients don't respond or stop due to mutations or progression. Recent studies at ASH 2024 explored combinations like pelabresib, bomedemstat, and elritercept with ruxolitinib, showing promise in improving symptoms, spleen volume reduction, and addressing cytopenias in MF patients.

The Essential Thrombocythemia (ET) market is set to grow significantly by 2034, driven by increasing disease prevalence and awareness. Key companies like Merck and PharmaEssentia are advancing treatments such as Bomedemstat and Ropeginterferon alfa-2b. ET, a rare blood disorder, is diagnosed through blood tests and genetic mutations, with treatments aiming to reduce thrombosis or bleeding risks.

Merck announces new data for approved and investigational medicines across multiple hematologic malignancies to be presented at the ASH Annual Meeting, including zilovertamab vedotin and nemtabrutinib. Over 20 abstracts will showcase the company's progress in clinical research, with a focus on novel modalities and therapeutic targets.

A phase 3 trial (NCT06456346) has begun to assess bomedemstat (MK-3543; IMG-7289) for essential thrombocythemia (ET) patients not previously treated with cytoreductive therapy. The Shorespan-007 trial will compare bomedemstat with standard-of-care hydroxyurea in treatment-naive ET patients, with primary end points including durable clinicohematologic response rate and secondary end points like duration of hematologic remission and event-free survival. Bomedemstat has received FDA orphan drug and fast track designations for ET and myelofibrosis.

A phase 3 clinical trial for essential thrombocythemia patients has launched, investigating bomedemstat as a potential new treatment. The trial, named Shorespan-007, aims to compare bomedemstat to standard chemotherapy, hydroxyurea, and is expected to conclude in May 2029.

Merck launched Shorespan-007, a Phase 3 trial evaluating bomedemstat for essential thrombocythemia (ET) patients not on cytoreductive therapy. Bomedemstat is compared to hydroxyurea in 300 ET patients, with primary and secondary endpoints focusing on response rates and symptom scores. Bomedemstat also has FDA Orphan Drug and Fast Track designations for ET and myelofibrosis, and a Priority Medicines designation for myelofibrosis by the EMA.

Merck's Phase III Shorespan-007 trial evaluates bomedemstat for essential thrombocythemia (ET) in patients not previously treated with cytoreductive therapy, comparing it to hydroxyurea. The trial aims to improve disease control and quality of life for ET patients, with endpoints including durable clinicohematologic response rate and patient-reported outcomes. Bomedemstat has received Orphan Drug and Fast Track designations for ET and myelofibrosis.

Merck initiates Shorespan-007, a Phase 3 trial evaluating bomedemstat for essential thrombocythemia (ET) patients not previously treated with cytoreductive therapy, aiming to address unmet needs in myeloproliferative neoplasms (MPNs).

Merck initiates Phase 3 trial, Shorespan-007, evaluating bomedemstat, an LSD1 inhibitor, for treating essential thrombocythemia (ET) patients not previously treated with cytoreductive therapy. The trial aims to compare bomedemstat with standard care chemotherapy, hydroxyurea, with a focus on durable clinicohematologic response rate and patient-reported outcomes. Bomedemstat holds FDA Orphan Drug and Fast Track Designations for ET and myelofibrosis.